What does Precirix do?
Precirix is a biotechnology company that specializes in developing innovative antibody-drug conjugates for targeted cancer therapy. The company focuses on enhancing the efficacy and safety of treatments by precisely delivering cytotoxic agents to cancer cells. Precirix aims to improve patient outcomes through its cutting-edge research and advanced technology in the field of oncology.
- Signals
-
Juridical warningJuridical warning
The legal status points to elevated risk (e.g. dissolution or bankruptcy).
Negative equityNegative equity € -15.66MEquity is negative: debts exceed assets (technically insolvent).
Reporting lossesReporting losses € -15.72MThe company reported a loss in the latest financial year.
Poor liquidityPoor liquidity 0.22The current ratio is below 1: may be insufficient to cover short-term debt.
Negative cashflowNegative cashflow € -13.69MOperating cash flow was negative in the latest financial year.
Negative EBITDANegative EBITDA € -10.00MEBITDA is negative: operating activities are loss-making.
Healthy social debtHealthy social debt 18.4%Social debts stay manageable relative to personnel costs.
Financial ratios
|
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
€
-5.54M
|
€
-1.41M
|
€
-742K
|
€
-1.26M
|
|
|
€
-10.00M
|
€
-4.01M
|
€
-3.68M
|
€
-4.75M
|
|
|
€
-15.72M
|
€
-9.66M
|
€
-15.22M
|
€
-16.96M
|
|
|
€
-15.66M
|
€
60K
|
€
9.72M
|
€
24.94M
|
|
|
-406.67%
|
0.41%
|
81.63%
|
88.26%
|
|
|
€
17.70M
|
€
14.42M
|
€
2.19M
|
€
3.32M
|
|
|
€
3.01M
|
€
9.13M
|
€
6.45M
|
€
23.59M
|
|
|
20.30
|
21.20
|
26.60
|
25.10
|
Publications 25
All publications- Rubriek Einde (Stopzetting, Intrekking Stopzetting, Nietigheid, Ger. Ak., Gerechtelijke Reorganisatie, Enz... - Ontslagen - Benoemingen 20/01/2026
- Statuten (Vertaling, Co?Rdinatie, Overige Wijzigingen, ?) 15/05/2025
- Ontslagen - Benoemingen 06/03/2025
- Diversen 28/11/2024
- Ontslagen - Benoemingen 13/11/2024
Frequently asked questions
Answers to the most common questions about Precirix, based on official government data and the filed annual accounts.
What is the VAT number of Precirix?
The VAT number of Precirix is BE0564.736.473.
How many employees work at Precirix?
In 2025, Precirix employed 20.30 full-time equivalents (FTE).
When was Precirix established?
Precirix was founded in 15-10-2014.
What is the official address of Precirix?
The official address of Precirix is Burgemeester Etienne Demunterl. 3 Jette 1090.
What is the legal form of Precirix?
The juridical form of Precirix is Public limited company (NV/SA).
What is the annual revenue of Precirix?
The 2025 accounts of Precirix do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.
What does Precirix do?
Precirix is a biotechnology company that specializes in developing innovative antibody-drug conjugates for targeted cancer therapy. The company focuses on enhancing the efficacy and safety of treatments by precisely delivering cytotoxic agents to cancer cells. Precirix aims to improve patient outcomes through its cutting-edge research and advanced technology in the field of oncology.
Is Precirix a reliable company?
Precirix is a registered Rechtspersoon with company number 0564.736.473 and can be verified through the official CBE database.
What is the credit limit of Precirix?
The estimated credit limit of Precirix is €0.
Is Precirix still active?
Precirix currently has the status "Vrijwillige ontbinding – vereffening" and is not active.